



Drug Regulatory Unit Botswana

Lisa Maria Urio
Pharmacist
Registration Section





DRU Mandate

- ▶ The DRU is the unit of the Ministry of Health responsible for ensuring that medicines used in the country are safe, effective and of good quality.
- ▶ To this end the unit is involved in the evaluation of all medicinal applications for registration, inspection of facilities where medicines are stored and distributed.
- ▶ The mandate extends to ensuring that once the products are registered, the quality of the circulating products is maintained.



Organogram




Contact Details

Name	Telephone Number	Email address
Dr. S. Selelo	+267 363 2064	sselelo@gov.bw
Mrs. P. Tsiu	+267 363 2821	ptsiu@gov.bw
Ms. S. Mogatle	+267 363 2381	smogatle@gov.bw
Mr. T. Mahupu	+267 363 2378	tmahupu@gov.bw
Mr. K. Baki	+267 363 2380	kbaki@gov.bw
Mr. Z. Joy	+267 363 2380	zjoy@gov.bw
Dr. N. Modutlwa	+267 363 2830	nmodutlwa@gov.bw
Ms. L. Urio	+267 363 2383	lurio@gov.bw
Mrs. N. Kago	+267 363 2376	nkago@gov.bw
Mr. S. Ramoroka	+267 363 2378	sramoroka@gov.bw
Mr. L. Koitsiwe	+267 363 2383	lkoitsiwe@gov.bw
Mr. R. Ganetsang	+267 363 2378	rganetsang@gov.bw


Functions of DRU

- ▶ Registration
 - Allopathic medicines
 - Complementary medicines
- ▶ Medicines control
 - Habit forming drugs (HFD)
 - Inspectorate
 - GMP inspections
 - Pharmacovigilance/Postmarketing surveillance




New medicine registration dossiers

- Receiving of application
- Pre-evaluation coding and entry into the database
- Assigning application numbers and acknowledging receipt to the applicant
- Evaluation/ Assessment
- Communication of queries to applicants



New medicine registration dossiers cont.

- Re-evaluation of resubmissions after queries are communicated to the applicants
- Pre registration discussions of the evaluation reports Preparation of reports for Drugs Advisory Board
- Registration/Rejection/Deferred with the Drugs Advisory Board
- Preparation of registration certificates and implementing other DAB decisions
- Communication with the applicants




Variations

- ▶ Drugs Regulatory Unit of Botswana implemented variation guidelines in June 2009 so any application before this date were not processed.
- ▶ Variation applications are received and entered into SIAMED(an electronic database).
- ▶ The Evaluator, using the Variations guidelines, evaluates the application and prepares the letter which notes the queries in the application.
- ▶ The evaluator then gives the letter to a second evaluator who evaluates to check for grammar and scientific correctness.




Variations cont.

- Second evaluator comments on the letter.
- Second evaluator gives the first evaluator the letter for finalisation.
- ▶ The evaluator then sends the letter of queries to the applicant, within two weeks.
- ▶ Upon receiving an adequate response, update the blue book if it's a variation which requires update of the blue book.




Import Control

- ▶ Assist the Customs Officers at border controls to control import of medicines into the country.
- ▶ The responsibility of the unit is to vet all import requests from all importers to ensure that only medicines that are allowed into the country are imported




Pharmacovigilance

- ▶ Relatively new
- ▶ ADR monitoring
 - Developed tools to report and capture ADR reports (guideline report form)
 - Sensitization of stakeholders (potential reporters of ADR) 3/4 of the country
 - Data collection and processing
 - Report generation for submission to WHO
 - PMS plan is expected in the application.(Some companies are already reporting ADRs)




Exemptions

- ▶ Process requests for exemption from registration of medicines for therapeutic use.
- ▶ There are 400 applications per year and the activities involved include
 - Receipt of applications
 - Checking of registration status of the medicines
 - Evaluation of information provided
 - Communication with applicants
 - Regular meetings with border staff to impress the importance of allowing only registered medicines




Clinical Trials

- ▶ Receipt of applications
- ▶ Assessment of applications
- ▶ Preparation of reports for committee review
- ▶ Presentation of the recommendations to the DAB
- ▶ Monitoring of the trial as they commence
- ▶ No GCP inspections currently




Interventions

- ▶ In 2008 the DRU had a backlog of about 1500 applications, following the report by SCMS a retreat system was introduced to reduce backlog
- ▶ In December 2010, a new way of outsourcing for evaluation of applications was introduced which includes a component of transfer of skills and has a better monitoring system




Interventions cont.

- ▶ Funds from other partners like PEPFAR have been used to train staff on evaluation of applications, use of SIAMED
- ▶ The Unit sought assistance from WHO Prequalification system to train staff members




Achievements

- ▶ As of April 2011 there are 160 applications pending evaluation compared to 1500 in 2007
- ▶ Currently there are 11 guidelines related to registration of medicines, compared to one guideline in 2008
- ▶ Applications are now submitted in CDs as well as one hard copy
- ▶ Improved quality of dossiers and reports




Achievements cont.

- ▶ Guidelines and application forms are now published on the Ministry of Health website
- ▶ SOPs are available for major activities
- ▶ A computer based registration system (SIAMED) is in use
- ▶ All dossiers are stored in dossier rooms which have the appropriate packaging and shelves




Achievements cont.

- ▶ A document management system (manual and computerized) is in place
- ▶ Registration certificates were issued from 2010
- ▶ A sample management system is in place. Samples are now being sent to the NDQCL for testing
- ▶ All registered products are now being monitored for variations




Challenges

- ▶ High attrition rate of staff
- ▶ Lack of experienced staff, majority of staff have less than two years experience
- ▶ Inadequate staff
- ▶ Establishing timelines due to lack of historical data
- ▶ Poor transport availability




Challenges cont.

- ▶ Lack of funds to conduct Good Manufacturing Practice inspection on pharmaceutical manufacturers
- ▶ Lack of office space
- ▶ Lack of expertise for troubleshooting for the narcotics software
- ▶ The use of outdated legal framework in medicines regulation
- ▶ Challenges with transparency and efficiency of service delivery




Next Steps

- ▶ Update list of products allowed in Botswana
- ▶ Update and develop other guidelines
- ▶ Improve capacity of staff
- ▶ To monitor the quality of drugs as they enter the country.



Next Steps cont.

- ▶ Conduct two consultancies this financial year
- ▶ Update listed products
- ▶ Develop more guidelines
- ▶ Review system of recognizing registration from other countries



Questions

